- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04832009
Reversing Glucose and Lipid-mediated Vascular Dysfunction (REGAL)
Reversing Glucose and Lipid-mediated Vascular Dysfunction (REGAL)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Hypertension, obesity, and insulin resistance are associated with elevated muscle sympathetic nerve activity (MSNA), which is important for blood pressure regulation. The measurement of MSNA is safely performed in humans using the microneurographic technique that involves recording sympathetic nerve activity projecting to skeletal muscle using a small microelectrode at the peroneal nerve near the knee.
The health of your blood vessels will be tested in this study, in addition to the activity of the nerves that control the blood vessels. The function of the nerves and blood vessels can be diminished by high blood glucose and lipids, and we will test the ability of a well-known antioxidant, ascorbic acid (vitamin C), to restore the function of the nerves and blood vessels.
Study Type
Enrollment (Anticipated)
Phase
- Early Phase 1
Contacts and Locations
Study Contact
- Name: Seth W Holwerda, PhD
- Phone Number: 9729223230
- Email: sholwerda@kumc.edu
Study Contact Backup
- Name: Davina A Clonch
- Phone Number: 9132266009
- Email: shoggirl@gmail.com
Study Locations
-
-
Kansas
-
Kansas City, Kansas, United States, 66103
- Recruiting
- University of Kansas Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Lean: BMI < 25 kg/m
- Normal insulin sensitivity: (calculation based on fasting glucose and insulin concentrations in blood)
- Middle-aged: 18-79 years
- Blood pressure: < 140 (systolic) and < 90 mmHg (diastolic
- Weight stable (+/- 5 lbs) for the previous 3 months
- Participants must be willing and able to discontinue taking any vitamin C or E supplements or omega-3 fatty acids beginning 2 weeks prior.
- Able and willing to provide written informed consent
Exclusion Criteria:
- Diabetes mellitus Type I or Type II: fasting glucose < 126 mg/dL and/or HbA1c < 6.5%
- Current smoker or History of smoking in the past 3 months.
- Hyperlipidemia: Fasting triglycerides < 250 mg/dL
- Hypertension: >130/80 mmHg
- History of heart disease (e.g., myocardial infarction, stent, heart attack, stroke, heart failure, valvular heart disease, cardiomyopathy)
- History of vascular disease (e.g., bypass, stroke)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Glucose Infusion
Hyperglycemia (glucose infusion) will receive an I.V. Glucose infusion with a co-infusion of ascorbic acid or placebo at your visit 2 and the alternative treatment of ascorbic acid or placebo will be given on the subsequent study visit 3.
|
Dextrose (20% intravenous solution) will be obtained from the Investigational Pharmacy located in the KU Clinical Research Center where studies take place.
After fasting for at least 8 hours, dextrose will be administered via antecubital vein at a standard rate of 4 mg/kg/min for 2 hours.
Other Names:
Saline will be obtained from the Investigational Pharmacy located in the KU Clinical Research Center where studies take place.
Will be administered via antecubital vein at 75 to 150 mL/hour for 2 hours.
Other Names:
(ASCOR) will be obtained from the KU Investigational Pharmacy located in the KU Clinical Research Center where studies will take place.
A priming bolus of 0.06 g ascorbic acid/kg fat free mass (FFM) dissolved in 100 mL of saline will be infused intravenously at 5 mL/min for 20 minutes, followed immediately by a "drip-infusion" of 0.02 g/kg FFM dissolved in 30 mL of saline administered over 2 hours at 0.5 mL/min.
The KU Investigational Pharmacy will randomize ascorbic acid or placebo (saline) for each participant.
|
Experimental: Lipid Infusion
Hyperlipidemia (lipid infusion) will receive an I.V. Lipid infusion with a co-infusion of ascorbic acid or placebo at your visit 2 and the alternative treatment of ascorbic acid or placebo will be given on the subsequent study visit 3.
|
Saline will be obtained from the Investigational Pharmacy located in the KU Clinical Research Center where studies take place.
Will be administered via antecubital vein at 75 to 150 mL/hour for 2 hours.
Other Names:
(ASCOR) will be obtained from the KU Investigational Pharmacy located in the KU Clinical Research Center where studies will take place.
A priming bolus of 0.06 g ascorbic acid/kg fat free mass (FFM) dissolved in 100 mL of saline will be infused intravenously at 5 mL/min for 20 minutes, followed immediately by a "drip-infusion" of 0.02 g/kg FFM dissolved in 30 mL of saline administered over 2 hours at 0.5 mL/min.
The KU Investigational Pharmacy will randomize ascorbic acid or placebo (saline) for each participant.
Intralipid ® 20% will be obtained from the Investigational Pharmacy located in the KU Clinical Research Center where studies take place.
After fasting for at least 8 hours, Intralipid ® 20% will be administered via antecubital vein at 0.75 mL/min for 2 hours Increases in circulating markers of oxidative stress peak within 2 hours of Intralipid ® 20% infusion in healthy adults (42).
An initial heparin bolus of 1000 UL followed by 200 U/hr infusion will be included to activate endothelial lipoprotein lipase and accelerate hydrolysis of fatty acids.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Efficacy of Infusion of Ascorbic Acid
Time Frame: Baseline
|
The difference in sympathetic-vascular transduction (mmHg) between ascorbic acid and placebo infusion will be taken as a measure of the modulation of SVT by oxidative stress.
|
Baseline
|
Efficacy of Infusion of Ascorbic Acid
Time Frame: 30 minutes
|
The difference in sympathetic-vascular transduction (mmHg) between ascorbic acid and placebo infusion will be taken as a measure of the modulation of SVT by oxidative stress.
|
30 minutes
|
Efficacy of Infusion of Ascorbic Acid
Time Frame: 60 minutes
|
The difference in sympathetic-vascular transduction (mmHg) between ascorbic acid and placebo infusion will be taken as a measure of the modulation of SVT by oxidative stress.
|
60 minutes
|
Efficacy of Infusion of Ascorbic Acid
Time Frame: 90 minutes
|
The difference in sympathetic-vascular transduction (mmHg) between ascorbic acid and placebo infusion will be taken as a measure of the modulation of SVT by oxidative stress.
|
90 minutes
|
Efficacy of Infusion of Ascorbic Acid
Time Frame: 120 minutes
|
The difference in sympathetic-vascular transduction (mmHg) between ascorbic acid and placebo infusion will be taken as a measure of the modulation of SVT by oxidative stress.
|
120 minutes
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Hypertension
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Protective Agents
- Micronutrients
- Vitamins
- Antioxidants
- Pharmaceutical Solutions
- Parenteral Nutrition Solutions
- Fat Emulsions, Intravenous
- Soybean oil, phospholipid emulsion
- Ascorbic Acid
Other Study ID Numbers
- 00147066
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hypertension
-
National Taiwan University Hospital Hsin-Chu BranchRecruitingHypertension,Essential | Hypertension, MaskedTaiwan
-
University of Alabama at BirminghamTroy UniversityCompletedHypertension | Hypertension, Resistant to Conventional Therapy | Uncontrolled Hypertension | Hypertension, White CoatUnited States
-
BayerCompletedPrimary HypertensionChina
-
Addpharma Inc.Completed
-
Columbia UniversityAgency for Healthcare Research and Quality (AHRQ)Active, not recruitingWhite Coat Hypertension | Hypertension,EssentialUnited States
-
Universidade Federal de Santa MariaCompletedHealthy Volunteers | Hypertension, EssentialBrazil
-
Sulaiman AlRajhi CollegesUnknownHypertension, Essential | β-hydroxybutyrate
-
Centre Chirurgical Marie LannelongueUnknownChronic Thrombo-embolic Pulmonary Hypertension and Pulmonary Arterial HypertensionFrance
-
Sheffield Teaching Hospitals NHS Foundation TrustUniversity of SheffieldCompletedIdiopathic Pulmonary Arterial Hypertension | Chronic Thromboembolic Pulmonary HypertensionUnited Kingdom
Clinical Trials on Dextrose 20 % in 500 ML Injection
-
Taipei Medical UniversityCompleted
-
Bumi HermanCompleted
-
Istanbul UniversityCompletedPain, PostoperativeTurkey
-
Christian Medical College and Hospital, Ludhiana...All India Institute of Medical Sciences, New Delhi; Indian Council of Medical... and other collaboratorsRecruitingIntracerebral Hemorrhagic StrokeIndia
-
Advanz PharmaAstellas Pharma US, Inc.CompletedAtrial FlutterUnited States, Canada, Denmark, Sweden
-
Advanz PharmaAstellas Pharma US, Inc.CompletedAtrial FibrillationUnited States, Canada, Sweden, Denmark
-
Clinical Hospital Centre ZagrebMerck Sharp & Dohme LLCCompleted
-
Kastamonu UniversityCompleted
-
Gruppo Oncologico Italiano di Ricerca ClinicaRecruitingMesotheliomas PleuralItaly
-
University Hospital, GhentCompletedRupture of the Anterior Cruciate Ligament With Instability of the Knee JointBelgium